Abstract
IntroductionThis Phase 3 study evaluated telaprevir (T) in combination with pegylated-IFN alfa-2a (P) and ribavirin (R) in well-characterised G1 prior-PR treatment failure patients including prior PR non-responders (null and partial)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have